– Significant unmet need for safe and effective oral therapies in UC for patients with inadequate response, loss of response or intolerance to conventional or advanced therapies SAN DIEGO--(BUSINESS ...
- Evaluating etrasimod 2 mg in patients with the clinical diagnosis of moderately to severely active ulcerative colitis (UC) - Significant unmet need for new effective oral therapies in UC SAN DIEGO, ...
SAN DIEGO--(BUSINESS WIRE)--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has completed full enrollment of the Phase 3 ELEVATE UC 52 trial evaluating the safety and efficacy of ...
SAN DIEGO, Sept. 16, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the first subject has been dosed in the ELEVATE UC 12 global Phase 3 trial evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results